Moffitt deepens partnership with biotech firm focused on novel cancer therapies

Lion Biotechnologies Inc. has two new agreements with Moffitt Cancer Center. The deals will help Moffitt’s efforts to lead the way in providing cutting-edge immunotherapies to cancer patients in Florida and beyond, James Mulé, associate center director of translational science at Moffitt, said in a press release. Lion (NASDAQ: LBIO) is a clinical-stage biotechnology co mpany focused on the development and commercialization of novel cancer immunotherapy products. The company signed a licensing…
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
This study has identified the TPG-1 proteoglycan as an antitumor agent and provided insights into TPG-1's molecular mechanism, suggesting a potential utility for applying this agent in cancer therapy.
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Cell Biology Source Type: research
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Immunotherapies Prove Their Mettle Against Kidney Cancer Adding immunotherapy to targeted cancer therapy boosted survival for kidney cancer...
Source: - Daily MedNews - Category: General Medicine Source Type: news
In conclusion, targeting peptides could guide DC-CIK to effectively and specifically kill tumor cells which were pre-coated with these targeting peptides and non-cell derived targeting peptide-loaded-DC-CIK may work as a novel means for cancer therapy. PMID: 30777479 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Publication date: February 2019Source: Brain, Behavior, and Immunity, Volume 76, SupplementAuthor(s): E.G. Vichaya, D.J. Estrada, B.G. Ford, J.M. Molkentine, D.W. Vermeer, P.D. Vermeer, C.M. Taniguchi, R. DantzerWhile fatigue is one of the mostly commonly reported side effects of cancer therapy, there is significant variability in intensity and persistence of this symptom. Understanding the factors accounting for this variation may provide insight into mechanisms underlying fatigue. An often overlooked issue is the possible influence of sex differences. The few studies that have been conducted employed patient-reported out...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
For years, cancer treatment was dominated by chemotherapy, radiation therapy, and stem cell transplantation. New insights into genetic characteristics of leukemic cells have initiated the development of the chimeric antigen receptor (CAR) T-cell therapy. This type of adoptive cell immunotherapy has been a breakthrough in the treatment of aggressive B-cell lymphoma and B-cell precursor acute lymphoblastic leukemia. In August 2018, the European Commission has approved the first CAR T-cell products – tisagenlecleucel (Kymriah®, Novartis) and axicabtagene ciloleucel (Yescarta®, Gilead) – for hematological n...
Source: Transfusion Medicine and Hemotherapy - Category: Hematology Source Type: research
In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry andWestern blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
sand Glioblastoma (GBM) is the most common type of primary brain tumor in adults. Despite recent advances in cancer therapy, including the breakthrough of immunotherapy, the prognosis of GBM patients remains dismal. One of the new promising ways to therapeutically tackle the immunosuppressive GBM microenvironment is the use of engineered viruses that kill tumor cells via direct oncolysis and via stimulation of antitumor immune responses. In this review, we focus on recently published results of phase I/II clinical trials with different oncolytic viruses and the new interesting findings in preclinical models. From synge...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: We intended to briefly summarize the current studies related to targeting the CSC antigens by cancer immunotherapy based on their properties. Moreover, we highlight that CSC antigens possess targeting activity in the treatment of cancer patients. PMID: 30714514 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Abstract Development of targeted cancer therapy requires a thorough understanding of mechanisms of tumorigenesis as well as mechanisms of action of therapeutics. This is challenging because by the time patients are diagnosed with cancer, early events of tumorigenesis have already taken place. Similarly, development of cancer immunotherapies is hampered by a lack of appropriate small animal models with autologous human tumor and immune system. In this article, we report the development of a mouse model of human acute myeloid leukemia (AML) with autologous immune system for studying early events of human leukemogene...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Immunotherapy | Partnerships | Science